TY  - CHAP
M1  - Book, Section
TI  - Repurposing Therapies for COVID-19
A1  - Go, Ronaldo C.
A2  - Go, Ronaldo C.
Y1  - 2022
N1  - 
T2  - Understanding Crisis in Critical Care
AB  - New  drug  development  is  expensive,  requires  at  least  10  years,  and  has  a  success  rate  of  only  2.01%.1  There  are  a  large  number  of  compounds  to  be  tested  and  large  number  of  randomized  control  trials  with  no  clinical  benefit  or  with  toxicities.2,3  There  would  also  be  a  significant  gap  between  the  need  and  the  availability  of  treatment.  During  the  coronavirus  disease  2019  (COVID-19)  pandemic,  drug  repurposing  was  used  to  identify  new  indications  of  existing  drugs.4–6  It  has  been  suggested  that  75%  of  known  drugs  can  be  used  for  repurposing,  re-profiling,  re-tasking,  or  rescue.6  Safety  of  these  drugs  have  already  been  tested.  Therefore,  this  technique  is  less  expensive,  and  allows  faster  utilization  via  phase  II  and  III  clinical  trials  and  compassionate  use.  
SN  - 
PB  - McGraw Hill
CY  - New York, NY
Y2  - 2024/04/20
UR  - accessanesthesiology.mhmedical.com/content.aspx?aid=1184737465
ER  -